Fournier gangrene is associated with increased length of stay and higher healthcare costs compared to non-perineal necrotizing soft tissue infections: a retrospective analysis of the National Inpatient Sample (2016–2020)

TL;DR

Fournier gangrene, a severe infection of the perineum, leads to longer hospital stays and higher costs than similar infections in other body areas, despite similar mortality rates.

Contribution

This study provides nationwide evidence that Fournier gangrene is associated with increased length of stay and healthcare costs compared to non-perineal necrotizing soft tissue infections.

Findings

Fournier gangrene was associated with a 1.99-day longer hospital stay compared to non-perineal NSTIs.

Hospital costs for Fournier gangrene were $37,809 higher than for non-perineal NSTIs.

Mortality rates were similar between Fournier gangrene and non-perineal NSTIs after adjustment.

Abstract

Fournier gangrene (FG) is a necrotizing soft tissue infection (NSTI) of the perineum. Recent retrospective studies from quaternary centers suggest improved outcomes and a potentially less aggressive clinical course for FG than non-perineal NSTIs. However, comprehensive nationwide data remain limited.

This retrospective cohort study analyzed the National Inpatient Sample (2016–2020) to compare outcomes between FG and non-perineal NSTIs. Adult patients undergoing surgical debridement with a diagnosis of FG or NSTI were identified using ICD-10 codes. Outcomes included in-hospital mortality, length of stay (LOS), hospital costs, and home discharge rates. Multivariable regression analyses adjusted for patient demographics, comorbidities, and hospital characteristics.

A total of 5,007 FG and 24,782 non-perineal NSTI patients were identified. Crude in-hospital mortality rates were 5.8% for FG and 5.4% for non-perineal NSTIs, with stable trends observed over five years. After adjustment, no significant difference in mortality was observed (adjusted odds ratio [aOR]: 1.04; 95% CI: 0.90–1.20). However, FG was associated with longer LOS (adjusted mean difference: 1.99 days; 95% CI: 1.53–2.46) and higher hospital costs ($37,809 higher; 95% CI: $29,540–$46,077). Home discharge rates were similar between groups (aOR: 0.97; 95% CI: 0.89–1.05).

Despite similar mortality rates, FG hospitalizations were associated with increased LOS and higher costs compared to non-perineal NSTIs. These findings may suggest potential nationwide disparities in FG care quality, particularly outside specialized referral centers. Further research is needed to understand if standardized care pathways tailored to FG may optimize management and reduce resource utilization.

Figures